Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update
Retrieved on:
Thursday, February 25, 2021
CY6463 administration resulted in improvement in the levels of various neuroinflammatory biomarkers, including alpha-2-macroglobulin (A2M) and Complement C3 (C3).
Key Points:
- CY6463 administration resulted in improvement in the levels of various neuroinflammatory biomarkers, including alpha-2-macroglobulin (A2M) and Complement C3 (C3).
- ADv Clinical Trial Initiation: The Company anticipates initiating a 12-week Phase 2a clinical trial in patients with ADv midyear.
- Cash Position:Cash, cash equivalents, and restricted cash balance onDecember 31, 2020 was approximately$58 million, as compared toapproximately$71milliononSeptember 30, 2020.
- For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion) and LinkedIn ( www.linkedin.com/company/cyclerion ).